Ajanta Pharma on Tuesday said its consolidated profit after tax declined by 5 per cent to Rs 151 crore for the fourth quarter ended March 2022.
The drug firm had reported a consolidated PAT (Profit After Tax) of Rs 159 crore in the January-March quarter of 2020-21 fiscal.
Revenue from operations rose to Rs 870 crore during the period under review from Rs 757 crore in the year-ago period, the Mumbai-based drug firm said in a regulatory statement.
For the year ended March 31, 2022, the company posted a PAT of Rs 713 crore. It was Rs 654 crore in FY21. Revenue from operations rose to Rs 3,341 crore last fiscal as against Rs 2,890 crore in 2020-21.
The company said its board has approved the issuance of bonus equity shares in the proportion of 1 share of Rs 2 each for every 2 shares of Rs 2 each. PTI MSS SHW SHW
To stay updated with the Latest Stock Market news, download our app here!
For editorial purposes, contact news@tradebrains.in
Start Your Stock Market Journey Today!
Want to learn Stock Market trading and Investing? Make sure to check out exclusive Stock Market courses by FinGrad, the learning initiative by Trade Brains. You can enroll in FREE courses and webinars available on FinGrad today and get ahead in your trading career. Join now!!